
Breast Chemotherapy Regimen v 3.5 Oct 2015
... after the start of subsequent doses. If the patient tolerates the previous cycles then cycles 2 and 3 may be monitored for 30 minutes post infusion and cycle 4 onwards does not require monitoring however this is unlicensed and the patient needs to be informed and consented Cycle Frequency: Loading d ...
... after the start of subsequent doses. If the patient tolerates the previous cycles then cycles 2 and 3 may be monitored for 30 minutes post infusion and cycle 4 onwards does not require monitoring however this is unlicensed and the patient needs to be informed and consented Cycle Frequency: Loading d ...
AuspAR: Cabazitaxel - Therapeutic Goods Administration
... use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as per ...
... use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as per ...
Hypersensitivity reactions to anticancer agents: Data mining of the
... adverse events, from such a large database. Recently developed data mining tools for pharmacovigilance have been successful at detecting signals that could not be found by individual case reviews and that warrant further investigation together with continuous surveillance. For this reason, data mini ...
... adverse events, from such a large database. Recently developed data mining tools for pharmacovigilance have been successful at detecting signals that could not be found by individual case reviews and that warrant further investigation together with continuous surveillance. For this reason, data mini ...
Ciprofloxacin sensitizes hormone-refractory prostate cancer cell
... of activity against solid tumors and hematological malignancies but has significant limitations in cancer treatment due to its severe toxicity, including myelosuppression and cardiotoxicity [21, 23, 38]. Monotherapy with doxorubicin has a relative modest activity in HRPC ...
... of activity against solid tumors and hematological malignancies but has significant limitations in cancer treatment due to its severe toxicity, including myelosuppression and cardiotoxicity [21, 23, 38]. Monotherapy with doxorubicin has a relative modest activity in HRPC ...
New Approval Mechanism for Breast Cancer using pathologic
... for the neoadjuvant treatment of patients with HER2‐positive, locally advanced, inflammatory or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. ...
... for the neoadjuvant treatment of patients with HER2‐positive, locally advanced, inflammatory or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. ...
NSABP B-40 Add-1 (2-15
... cause wound healing problems for patients who undergo surgery while receiving the drug. There have also been a few reports of patients receiving bevacizumab in other trials who developed complications with wound healing due to skin problems such as leg ulcers. These wound healing problems have been ...
... cause wound healing problems for patients who undergo surgery while receiving the drug. There have also been a few reports of patients receiving bevacizumab in other trials who developed complications with wound healing due to skin problems such as leg ulcers. These wound healing problems have been ...
Gemcitabine
... capecitabine/docetaxel in women with metastatic breast cancer who had received prior anthracycline therapy. This study found no significant difference in efficacy between the two treatment regimens in terms of objective response rate, progression-free survival, duration of response, or time-to-progr ...
... capecitabine/docetaxel in women with metastatic breast cancer who had received prior anthracycline therapy. This study found no significant difference in efficacy between the two treatment regimens in terms of objective response rate, progression-free survival, duration of response, or time-to-progr ...
chemotherapy - Breast Cancer Research Centre WA
... Therapy can include: chemotherapy hormonal therapy the targeted drug Trastuzumab (Herceptin) radiation therapy or a combination of treatments ...
... Therapy can include: chemotherapy hormonal therapy the targeted drug Trastuzumab (Herceptin) radiation therapy or a combination of treatments ...
Docetaxel
Docetaxel (as generic or under the trade name Taxotere or Docecad) is a clinically well-established anti-mitotic chemotherapy medication that works by interfering with cell division. Docetaxel is approved by the FDA for treatment of locally advanced or metastatic breast cancer, head and neck cancer, gastric cancer, hormone-refractory prostate cancer and non small-cell lung cancer. Docetaxel can be used as a single agent or in combination with other chemotherapeutic drugs as indicated depending on specific cancer type and stage.Docetaxel is a member of the taxane drug class, which also includes the chemotherapeutic medication paclitaxel. Although docetaxel remains twice as potent as paclitaxel (due to docetaxel’s effect on the centrosome of the mitotic spindle), the two taxanes have been observed to have comparable efficacy. Several recent articles have found ""no evidence that regimens containing docetaxel yield greater benefits than those including paclitaxel."" While efficacy between the two agents has been observed to be equivalent, paclitaxel may cause fewer side effects. Additionally, it has been noted that docetaxel is prone to cellular drug resistance via a variety of different mechanisms.The optimal dose scheduling of taxanes remains unconfirmed, but most studies find significant mortality benefit following either a three-week or a one-week administration schedule. While a 2010 article in Current Clinical Pharmacology states, ""weekly administration has emerged as the optimal schedule,"" the official docetaxel package insert recommends administration every three weeks. Important toxicities to note include neutropenia, febrile neutropenia and neurosensory disturbances. Such toxicities have been well documented in Phase II and Phase III clinical trials and can be anticipated and subsequently managed.Docetaxel is marketed worldwide under the name Taxotere by Sanofi-Aventis as well as Docefrez by Sun Pharma Global and Zytax by Zydus. Annual sales of Taxotere in 2010 were Euro 2.122 billion ($US 3.1 billion). The patent expired in 2010.Clinicians sometimes use the abbreviation ""TXT"" for docetaxel, although (like many medical abbreviations) it is not a unique identifier.